Indian Regulations Cap Drug Prices; Pharma Companies’ Profits Likely Impacted
Reuters: India caps prices of 108 more medicines; drugmakers to take hit
“India’s pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories, and Ranbaxy Laboratories Ltd…” (Siddiqui, 7/14).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.